Updated feasibility and reproducibility results of multi-institutional study of noninvasive breast tumor bed boost

详细信息    查看全文

• 作者：Jessica Schuster¹ ; ¹³ ; ^{Jessica.moore84@hotmail.com} ; Christopher Chipko¹ ; Michael Kasper² ; Sandra Sha³ ; Douglas Ciuba⁴ ; James Petrikas⁵ ; Anand Kuruvilla⁶ ; Ravichandra Sandrapaty⁷ ; Coral Quiet⁸ ; Cynthia Anderson⁹ ; Rashmi Benda¹⁰ ; David Wazer¹¹ ; Jaroslaw Hepel¹² ; Douglas Arthur¹
• 关键词：High dose rate ; Noninvasive breast brachytherapy ; Breast boost
• 刊名：Brachytherapy
• 出版年：2016
• 出版时间：November-December 2016
• 年：2016
• 卷：15
• 期：6
• 页码：804-811
• 全文大小：778 K
• 卷排序：15

文摘

To report updated feasibility and reproducibility results for high-dose-rate noninvasive breast brachytherapy (NIBB) for tumor bed boost with whole breast radiation therapy (WBRT) in the setting of expanded patient and treatment facility number.Methods and MaterialsFifteen independent community-based and academic centers reported 518 early-stage breast cancer patients from July 2007 to February 2015 on a privacy-encrypted online data registry. All patients' treatment included lumpectomy followed by combination of WBRT and NIBB. NIBB was completed with commercially available (AccuBoost, Billerica, MA) mammography-based system using high-dose-rate 192Ir emissions along orthogonal axes. Harvard scale was used to grade cosmesis.ResultsTotal patient cohort had median followup of 12 months (1–75 months) with subset of 268 having available cosmesis. Greater than 2- and 3-year followup was 29% and 14%, respectively. Entire cohort had 97.4% excellent/good (E/G) breast cosmesis and freedom from recurrence of 97.6% at the final followup. WBRT timing with respect to NIBB delivery demonstrated no statistically significant difference in E/G cosmesis. Achieved E/G cosmesis rate was also not statistically significant (χ2p-value = 0.86) between academic and community institutions with 97.8% vs. 96.6%.ConclusionsNIBB represents an alternative method for delivery of breast tumor cavity boost that has shown feasibility in a diverse group of both academic and community-based practices with reproducible early cosmesis and tumor control results. Recommendations are updated noting ideal timing of boost delivery likely to be before or early during WBRT given equal cosmesis and less documented treatment discomfort.